(Q37791751)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864362%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

title

Advanced bladder cancer: new agents and new approaches. A review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864362%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864362%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Emilio Sacco

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864362%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Giuditta Chiloiro

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864362%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

2

Marco Racioppi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864362%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

7

Francesco Pinto

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864362%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

author name string

Andrea Volpe

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864362%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Alessandro D'Addessi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864362%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Francesco Marangi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864362%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Angelo Totaro

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864362%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Sandra Battaglia

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864362%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Pier Francesco Bassi

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864362%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

publication date

22 September 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864362%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864362%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864362%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864362%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

page(s)

9-16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864362%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

cites work

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

Cystectomy for bladder cancer: a contemporary series

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

The systemic treatment of advanced and metastatic bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

Phase III comparison of cisplatin alone versus cisplatin, doxorubicin and cyclophosphamide in the treatment of bladder (urothelial) cancer: a Southeastern Cancer Study Group trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. The French Federation of Cancer Centers experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

Gemcitabine and cisplatin for advanced, metastatic bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

Gallium nitrate in advanced bladdercarcinoma: Southwest oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

Treatment of advanced transitional cell carcinoma of the bladder with continuous-infusion gallium nitrate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

A Phase II study of oxaliplatin in urothelial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

A phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

The voiding pattern in infants with dilating reflux

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

Farnesyltransferase inhibitor SCH-66336 downregulates secretion of matrix proteinases and inhibits carcinoma cell migration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

Review Article: The Role of Ras Superfamily Proteins in Bladder Cancer Progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

Histone deacetylase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

Novel approach of human epidermal growth factor receptor 2 detection in noninvasive and invasive transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

Expression of the epidermal growth factor receptor family in normal and malignant urothelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.022

10.1016/J.UROLONC.2010.03.022

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864362%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference